SU1498

(E)-3-(3,5-Diisopropyl-4-hydroxyphenyl)-2-[(3-phenyl-n-propyl)amino-carbonyl]acrylonitrile

PRODUCT ANALYSIS SHEET

Catalog Number:	PHZ1224
Lot Number:	See product label
Quantity:	5 mg
Appearance:	Pale yellow solid. Packaged under inert gas.
Molecular Formula:	$C_{25}H_{30}N_2O_2$
Molecular Weight:	390.5
Purity:	≥95%, as determined by HPLC
Summary:	SU1498 is a potent, selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as Flk-1 and KDR) kinase activity. SU1498 inhibits signaling arising from VEGFR2 stimulation, including activation of ERK1&2. In whole tissue studies, SU1498 inhibits angiogenesis, as assessed by the chorioallantoic membrane (CAM) assay and capillary tube formation, and inhibits VEGF-induced vascular permeability. Weak inhibition of PDGF receptor, EGF receptor, and ErbB-2 (HER2) is observed with higher SU1498 concentrations.
Biological Activity:	Flk-1 kinase: IC_{50} = 700 nM EGF receptor: IC_{50} >100 μM PDGF receptor: IC_{50} >50 μM HER-2: IC_{50} >100 μM
Solubility:	Soluble in DMSO.
Sterility:	This product is not sterile.
Storage:	Store, as supplied, at –20°C, protected from light. Upon solubilization, apportion into working aliquots and store at –20°C. Avoid repeated freeze/thaw cycles. Solutions are stable at –20°C for up to one month.
Expiration Date:	Expires one year from date of receipt when stored as instructed.
Related Products:	VEGFR [pY951] antibody, Cat. # 44-1040 VEGFR2 [pY1054] antibody, Cat. # 44-1046 VEGFR2 [pYpY1054/1059] antibody, Cat. # 44-1047G VEGFR2 [pY1214] antibody, Cat. # 44-1052 VEGFR2 pan antibody, Cat. # 44-1053G
Caution:	Avoid contact with eyes, skin, and mucous membranes. Wear protective clothing when handling this product. Not for human use.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

References:

Strawn, L.M., et al. (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res. 56(15):3540-3545.

Jin, K., et al. (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Nat'l. Acad. Sci. USA 99(18):11946-11950.

Boguslawski, G., et al. (2004) SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J. Biol. Chem. 279(7):5716-5724.

Wang, L., et al. (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35(7):1732-1737.

Yamamoto, K., et al. (2005) Fluid shear stress induces differentiation of Flk-1-positive embryonic stem cells into vascular endothelial cells in vitro. Am. J. Physiol. Heart Circ. Physiol. 288(4):H1915-H1924.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHZ1224 (Rev 1.1) (DCC-08-1232)

invitrogen™